Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4637709 | 0.94 | ALDH1A1 (0.42) | IDH1ALDH1A1TSHRGRM2GAA | |
| SCHEMBL4705403 | 0.86 | RORB (0.41) | IDH1GPBAR1GRM2CDC7 | |
| SCHEMBL4638005 | 0.81 | GPBAR1 (0.40) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL4705766 | 0.81 | ALDH1A1 (0.37) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL4639379 | 0.80 | ALDH1A1 (0.38) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL4705450 | 0.80 | RORB (0.42) | ALDH1A1TSHRGRM2CDC7GAA | |
| SCHEMBL6385074 | 0.80 | GPBAR1 (0.39) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL4638055 | 0.79 | ALDH1A1 (0.38) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL4709658 | 0.79 | ALDH1A1 (0.38) | IDH1GPBAR1ALDH1A1TSHRGRM2 | |
| SCHEMBL6389497 | 0.79 | IDH1 (0.42) | IDH1GPBAR1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179804-B2 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050239776-A1 | Tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1501808-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091227-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239776-A1 | Tachykinin receptor antagonists | TACR2, TACR1, PROKR1 | IDH1 4314/4885GPBAR1 101/4885ALDH1A1 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.